

Novonesis Q1 2024 at a glance

4%

Novonesis organic sales growth

Novonesis maintains the 2024 outlook of


5-7%

organic sales growth...

...with an adjusted EBITDA margin of around

35%

Sales by business area



Food & Health Biosolutions, 3%*

- Food & Beverages (Novozymes' Food & Beverage and Chr. Hansen's Food Cultures & Enzymes) 6%*
- Human Health (Novozymes' Human Health and Chr. Hansen's Human Health) -5%*

Planetary Health Biosolutions, 5%*

- Household Care (Novozymes' Household Care) 15%*
- Agriculture, Energy & Tech (Novozymes' Bioenergy, Agriculture & Animal Health/Nutrition, Grain & Tech Processing and Chr. Hansen's Animal & Plant Health) 0%*


Sales by geography

Europe, the Middle East & Africa
2%*

North America
-1%*

Asia Pacific
13%*

Latin America
10%*



*Organic sales growth

% of sales